The Biological Variability of Plasma Ceramides in Healthy Subjects.

RCV atherosclerotic cardiovascular disease reference change value sphingolipids

Journal

The journal of applied laboratory medicine
ISSN: 2576-9456
Titre abrégé: J Appl Lab Med
Pays: England
ID NLM: 101693884

Informations de publication

Date de publication:
30 06 2022
Historique:
received: 17 09 2021
accepted: 01 12 2021
pubmed: 30 1 2022
medline: 6 7 2022
entrez: 29 1 2022
Statut: ppublish

Résumé

Ceramides are bioactive lipid species that mediate numerous cell-signaling events. Elevated plasma ceramides concentration constitutes a risk factor for several pathologies. Multiple studies have affirmed the plasma concentrations of 4 specific ceramides (Cer16:0, Cer18:0, Cer24:0, and Cer24:1) can predict cardiovascular disease risk. Furthermore, these ceramides can be altered by many lipid-lowering therapies. Understanding the biological variability within an individual, and within a population, will further inform the clinical use of plasma ceramides as a biomarker. In this study, we aimed to define the intra- and interbiological variability of ceramides in a healthy reference population in a weekly and monthly manner. Fasting plasma from 24 healthy adults was collected daily (5 days), weekly (4 weeks), and monthly (7 months). Ceramide concentrations were measured with liquid chromatography-mass spectrometry (LC-MS). For analysis, we used random-effects regression models to estimate variance components. The analytical variability was smaller compared to the biological variability overall. The greatest variation reported was between-subject variation for all ceramide species. The critical difference-reference change value (RCV) for within-subject variations monthly were 0.07 mcmol/L (Cer16:0), 0.04 mcmol/L (Cer18:0), 1.09 mcmol/L (Cer24:0), and 0.27 mcmol/L (Cer24:1). The index of individuality (IOI) of ceramides were 0.82 (Cer16:0), 0.96 (Cer18:0), 1.06 (Cer24:0), and 0.89 (Cer24:1). The most consistent ceramide species was Cer18:0 with the lowest within- and between-subject critical differences in weekly and monthly measurements. Overall, this study demonstrates that the variability of ceramide concentrations at different time points is minimal within individuals, allowing a single draw to be sufficient at least in a yearly time frame.

Sections du résumé

BACKGROUND
Ceramides are bioactive lipid species that mediate numerous cell-signaling events. Elevated plasma ceramides concentration constitutes a risk factor for several pathologies. Multiple studies have affirmed the plasma concentrations of 4 specific ceramides (Cer16:0, Cer18:0, Cer24:0, and Cer24:1) can predict cardiovascular disease risk. Furthermore, these ceramides can be altered by many lipid-lowering therapies. Understanding the biological variability within an individual, and within a population, will further inform the clinical use of plasma ceramides as a biomarker. In this study, we aimed to define the intra- and interbiological variability of ceramides in a healthy reference population in a weekly and monthly manner.
METHODS
Fasting plasma from 24 healthy adults was collected daily (5 days), weekly (4 weeks), and monthly (7 months). Ceramide concentrations were measured with liquid chromatography-mass spectrometry (LC-MS). For analysis, we used random-effects regression models to estimate variance components.
RESULTS
The analytical variability was smaller compared to the biological variability overall. The greatest variation reported was between-subject variation for all ceramide species. The critical difference-reference change value (RCV) for within-subject variations monthly were 0.07 mcmol/L (Cer16:0), 0.04 mcmol/L (Cer18:0), 1.09 mcmol/L (Cer24:0), and 0.27 mcmol/L (Cer24:1). The index of individuality (IOI) of ceramides were 0.82 (Cer16:0), 0.96 (Cer18:0), 1.06 (Cer24:0), and 0.89 (Cer24:1). The most consistent ceramide species was Cer18:0 with the lowest within- and between-subject critical differences in weekly and monthly measurements.
CONCLUSIONS
Overall, this study demonstrates that the variability of ceramide concentrations at different time points is minimal within individuals, allowing a single draw to be sufficient at least in a yearly time frame.

Identifiants

pubmed: 35092283
pii: 6517181
doi: 10.1093/jalm/jfac002
doi:

Substances chimiques

Biomarkers 0
Ceramides 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

863-870

Informations de copyright

© American Association for Clinical Chemistry 2022. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Auteurs

Paola Ramos (P)

Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.

Sarah M Jenkins (SM)

Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN.

Leslie J Donato (LJ)

Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.

Stacy J Hartman (SJ)

Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.

Amy Saenger (A)

Department of Laboratory Medicine and Pathology, Hennepin Healthcare/HCMC, Minneapolis, MN.
Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN.

Nikola A Baumann (NA)

Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.

Darci R Block (DR)

Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.

Allan S Jaffe (AS)

Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
Department of Cardiology, Mayo Clinic, Rochester, MN.

Jeffrey W Meeusen (JW)

Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH